Market Overview

Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant


vTv Therapeutics Inc (NASDAQ: VTVT) shares have outperformed Axovant Sciences Ltd (NASDAQ: AXON) shares by 63 percent since Chardan recommended owning the former over the latter in January 2016.

The Analyst

Chardan analyst Gbola Amusa has a Neutral rating on Axovant and a $2 price target.

The Thesis

Chardan's premise behind its earlier recommendation of owning vTv Therapeutics over Axovant was based on the former having a Phase 3 asset – azeliragon - in Alzheimer's disease, Amusa said in a Thursday note. The analyst said azeliragon data was superior over Axovant's RVT-101 data.

Notwithstanding several parallels between azeliragon and RVT-101 programs, the analyst said a striking difference existed in the valuations of both companies at the time of his 2016 call. Compared to Axovant's $1.7 billion market-cap in Jan. 2016, vTv Therapeutics had a paltry valuation of C$200 million, the analyst noted.

With Chardan's bearish thesis on Axovant having played out following the failed pivotal late-stage MINDSET trial that evaluated the company's intepirdine in mild-to-moderate Alzhiemer's disease, the firm said valuations of Axovant ($168 million) and vTv Therapeutics ($156 million) have now converged.

Thus, the call to close out to pair trade.

Price Action

Over the past year, Axovant has lost about 90 percent compared to a more modest 20 percent drop by vTv Therapeutics.

Related Links:

Neurotrope Alzheimer's Candidate Could Generate Revenue Beginning In 2024, Analyst Says

Latest Ratings for AXON

Dec 2018UpgradesHoldBuy
Jan 2018DowngradesOutperformMarket Perform
Jan 2018UpgradesSellNeutral

View More Analyst Ratings for AXON
View the Latest Analyst Ratings

Posted-In: Chardan Gbola AmusaAnalyst Color Analyst Ratings


Related Articles (AXON + VTVT)

View Comments and Join the Discussion!

Latest Ratings

LOWRBC CapitalMaintains129.0
MARRBC CapitalMaintains148.0
CRLSunTrust Robinson HumphreyMaintains162.0
CFRSunTrust Robinson HumphreyMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Omeros Elevated By Medicare Reimbursement And OMS721 Progress, Says Maxim

Trump's $60B Tariff Plan Rattles Markets, Chinese Tech Stocks